My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Metformin + Glimepiride

Metformin + Glimepiride

What Is Glimepiride (Amaryl)?

Glimepiride is the generic name of the prescription drug Amaryl, used to treat patients with type 2 diabetes.

Glimepiride belongs to a class of drugs known as sulfonylureas.

It stimulates the pancreas to produce insulin and helps the body use insulin more efficiently.

The drug can also decrease the chances that someone will develop life-threatening complications of type 2 diabetes.

The drug was approved by the FDA in 1995 and is manufactured by Sanofi-Aventis.

Glimepiride comes in tablet form and is usually taken once a day. It may be used alone, or in combination with insulin or another oral medication such as metformin.

Your doctor will probably start you on a low dose of the medication and gradually increase your dose if needed.

If you've taken glimepiride for a long period of time, the drug may not control blood sugar as well as it did when you first started the treatment. Your doctor will adjust the dosage as needed.

Why it's used

Glimepiride is used to reduce high blood sugar levels in people with type 2 diabetes. It’s used in combination with a healthy diet and exercise.

This medication may be used with insulin or other types of diabetes drugs to help control your high blood sugar.

How it works

Glimepiride belongs to a class of drugs called sulfonylureas. A class of drugs is a group of medications that work in a similar way. These drugs are often used to treat similar conditions.

Glimepiride helps your pancreas to release insulin. Insulin is a chemical that your body makes to move sugar (glucose) from your bloodstream into your cells. Once the sugar enters your cells, they can use it as fuel for your body.

With type 2 diabetes, your body doesn’t make enough insulin, or it can't properly use the insulin that it makes, so the sugar stays in your bloodstream. This causes high blood sugar levels (hyperglycemia).


A literature search for RCTs on glimepiride and metformin was conducted on the bibliographic databases, including PubMed, Cochrane Library and ScienceDirect, from their inceptions to 25 Mar 2013. All RCTs were selected according to pre-specified eligibility criteria. The quality of articles was assessed with the Cochrane’s risk of bias tool. Statistical meta-analysis evaluated the overall effects and biochemical indices of T2DM. Sensitivity and subgroup analyses evaluated the robustness and explained the heterogeneity of the results. Begg and Egger’s tests quantified possible publication biases. Results were represented as "standard mean difference or odds ratio [95% confidence internals] P value".


Metformin was not significantly better than glimepiride in glycemic control of T2DM, suggesting that glimepiride would be a good choice second to metformin in the monotherapy of T2DM.

Glimepiride + Metformin and Other Contraindications

Hypersensitivity diabetic ketoacidosis (DKA); renal dysfunction; CHF (CHF), patients undergoing radiological studies; acute or chronic metabolic acidosis. Pregnancy, lactation.